Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Epstein-Barr Virus Infections 6Sarcoma, Kaposi 4Lymphoproliferative Disorders 4Cytomegalovirus Infections 4Nasopharyngeal Carcinoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Glioblastoma 3Multi-centric Castleman's Disease 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma 2Hodgkin Disease 2Acquired Immunodeficiency Syndrome 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Stomach Neoplasms 1Solid Tumor, Adult 1Sezary Syndrome 1Sarcoma 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Mycosis Fungoides 1Multiple Myeloma 1

Interventions

Exercise 35Therapeutics 30Modafinil 21Yoga 17Surveys and Questionnaires 16Methylphenidate 16Psychiatric Rehabilitation 14Acupuncture Therapy 11Educational Status 9Walking 8Early Intervention, Educational 8Cognitive Behavioral Therapy 8Ultraviolet Therapy 7Control Groups 7Therapeutic Touch 6Physical Therapy Modalities 6Mental Status and Dementia Tests 6Exercise Therapy 6Acceptance and Commitment Therapy 6Sugars 5Qigong 5Palliative Care 5Counseling 5Standard of Care 4Saline Solution 4Methods 4Epoetin Alfa 4Dexamethasone 4Behavior Therapy 4Acupressure 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fatigue × Valganciclovir × Clear all
NCT00478465 2022-05-27

Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)

Stanford University

Phase 1/2 Completed
30 enrolled

Fatigue, Herpes Simplex, Fatigue Syndrome, Chronic, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡